Understand the source comparison
Peptides vs SARMs: Research Application Comparison
The following table compares peptides vs SARMs across critical research parameters: Mechanism of Action Receptor-mediated signaling triggering endogenous hormone release (GH, IGF-1, immune modulators) Direct androgen receptor agonism in muscle/bone tissue with
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The following table compares peptides vs SARMs across critical research parameters:
- Mechanism of Action
- Receptor-mediated signaling triggering endogenous hormone release (GH, IGF-1, immune modulators)
- Direct androgen receptor agonism in muscle/bone tissue with reduced prostate activity
- Peptides preserve axis integrity; SARMs override it
- FDA Approval Status
- Some approved (Sermorelin, Tesamorelin for specific indications); most sold as research compounds
- Zero FDA-approved therapeutic applications as of 2026
- Peptides have established clinical precedent
- Legal Classification
- Unscheduled; legal for research use; subject to FDA biologics oversight when marketed for humans
- Unscheduled but illegal to market for human consumption; proposed Schedule III classification未通过
- Peptides have clear regulatory pathway
- HPG Axis Suppression
- Minimal to none—negative feedback intact
- Moderate to severe—LH/FSH suppression occurs at therapeutic doses in 70–90% of subjects
- Peptides allow continued endogenous production
- Hepatotoxicity Risk
- None (bypasses first-pass metabolism)
- Elevated ALT/AST in 15–25% at moderate doses due to oral administration
- Peptides eliminate liver enzyme concern
- Half-Life & Dosing
- Short (1–4 hours most peptides; 5–8 days for modified analogues); requires refrigeration
- Long (16–36 hours); stable at room temperature; once-daily oral dosing
- Peptides demand stricter handling; SARMs more convenient
- Tissue Selectivity Mechanism
- Receptor distribution + baseline tissue regenerative capacity
- Differential AR coactivator recruitment in muscle vs prostate
- Both achieve selectivity through distinct pathways
- Purity Verification Standard
- HPLC, mass spec, amino acid sequencing standard for research-grade suppliers
- Rarely available—most sources lack third-party COA; frequent contamination with prohormones
- Peptides meet biotech research standards
- Research Evidence Base
- Decades of clinical trial data for many compounds (BPC-157 in ulcer models, Thymosin Alpha-1 in immune trials)
- Limited Phase I/II data; most human evidence is anecdotal or gray-market observational
- Peptides have peer-reviewed mechanistic foundation
- Recovery/PCT Requirement
- None—axis not suppressed
- Often required—Nolvadex or Clomid to restore LH/FSH post-cycle
- Peptides avoid post-cycle intervention